Drug Trial Radar · NCT00822393
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
570
Actual
Start
Nov 24, 2008
Primary completion
Jan 25, 2018
Study completion Jan 25, 2018
Sponsor
- Lead sponsor
- medac GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based conditioning therapy with reduced intensity i.v. Busulfan-based conditioning in adult AML and MDS patients at increased risk for standard conditioning therapies. The protocol is based on results of previous phase I/II trials evaluating Treosulfan/Fludarabine conditioning prior to allogeneic haematopoietic stem cell transplantation. The reference arm (reduced intensity i.v. Busulfan/Fludarabine) is considered to be accepted medical practice for the study patient population.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
BusulfanDrug
4 x 0.8 mg/kg/d Intravenous Day -4 and -3
TreosulfanDrug
10 g/m2/d Intravenous Day -4, -3, -2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: within 2 years after transplantation
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Helsinki University Central Hospital, Dept. of Medicine
Helsinki, Finland
Centre Hospitalier Lyon Sud
Lyon, France
Hopital Saint-Louis
Paris, France
Universitätsklinikum Koeln, Stammzelltransplantation
Cologne, Germany
Universitätsklinikum Carl Gustav Carus Dresden, Med. Klinik I
Dresden, Germany
Klinik für Knochenmarktransplantation
Essen, Germany
Malteser Krankenhaus St. Franziskus-Hospital
Flensburg, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsmedizin Goettingen, Haematolgie und Onkologie
Göttingen, Germany
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Friedrich-Schiller-Universität Jena
Jena, Germany
Universitätsklinikum Leipzig, Haematologie, internistische Onkologie
Leipzig, Germany
Johannes-Gutenberg-Universität Mainz, III. Medizinische Klinik
Mainz, Germany
Klinikum Rechts der Isar der TU München, III. Med. Klinik
München, Germany
Universitätsklinikum Münster
Münster, Germany
Klinikum Nürnberg, 5. Medizinische Klinik
Nuremberg, Germany
Klinikum Oldenburg gGmbH
Oldenburg, Germany
Klinikum der Universität Regensburg
Regensburg, Germany
Universität Rostock
Rostock, Germany
Universität Tübingen
Tübingen, Germany
Stiftung Deutsche Klinik für Diagnostik
Wiesbaden, Germany
Klinikum der Universität Würzburg
Würzburg, Germany
St. Istvan and St. Laszlo Hospital of Budapest
Budapest, Hungary
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy
Hematology University of Brescia
Brescia, Italy
Scientific Institute H. San Raffaele
Milan, Italy
Ospedale Civile Pescara
Pescara, Italy
Policlinico Umberto I Univ. La Sapienza
Rome, Italy
Clinica Ematologica ed Unita di Terapie Cellulari 'Carlo Melzi'
Udine, Italy
Policlinico GB Rossi (Borgo Roma), Div. di Ematologia
Verona, Italy
Medical University of Gdansk
Gdansk, Poland
Silesian Medical University
Katowice, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.